机构：[1]Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China[2]Division of Thoracic Tumor Multimodality Treatment, Cancer Center and National Medical Products Administration key Laboratory for Clinical Research and Evaluation of Innovative Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[3]Department of Oncology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China[4]Department of Pulmonary and Critical Care Medicine, Huashan Hospital, Fudan University, Shanghai, China[5]Institute of Immunotherapy, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China[6]Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China广东省人民医院[7]Institute for Translational Brain Research, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Fudan University, Shanghai, China[8]Department of Thoracic Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China浙江省肿瘤医院[9]Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China[10]Department of Thoracic Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China[11]Department of Neurosurgical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China[12]Department of Radiation Oncology, Fujian Cancer Hospital & Fujian Medical University Cancer Hospital, Fuzhou, China
Lung cancer patients with leptomeningeal metastases (LMs) suffer from severe clinical symptoms, poor quality of life, narrow diagnostic and therapeutic time windows, low response to standard treatments, short survival periods, and poor prognoses. At present, there is a lack of precise diagnosis and treatment pathways and relevant consensus for LMs of lung cancer. In order to better guide the clinical diagnosis and treatment of LMs of lung cancer in an early, reasonable, and safe way, the experts of the Neurological Tumor Specialist Committee of the Chinese Society of Clinical Oncology (CSCO) have formulated this consensus based on the actual diagnosis and treatment of LMs of lung cancer in China, with reference to the latest research data, relevant guidelines and consensus, and the experts' clinical experience, as well as the results of experts' polling on the pre-set issues of LMs. The consensus focuses on diagnosing LMs, stratified management, efficacy evaluation systems, treatment strategies, common complications, and palliative care. It gives recommendations in each of the five aspects to provide clinicians with suggestions and references for diagnosing and treating LMs in lung cancer.
第一作者机构：[1]Department of Medical Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing Chest Hospital, Capital Medical University, Beijing, China
通讯作者：
推荐引用方式(GB/T 7714)：
Lin Gen,Wang Yongsheng,Xin Tao,et al.Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer[J].THORACIC CANCER.2025,16(11):doi:10.1111/1759-7714.70088.
APA：
Lin, Gen,Wang, Yongsheng,Xin, Tao,Zhang, Ding,Zhang, Qiuyu...&Hong, Yaping.(2025).Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.THORACIC CANCER,16,(11)
MLA：
Lin, Gen,et al."Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer".THORACIC CANCER 16..11(2025)
